Article Text
How to understand them
Prognostic models
Abstract
An appreciation of prognosis is essential for effective clinical practice, in neurology as in other fields. Predicting risk of a poor outcome in individuals, or at least in well-defined groups of individuals, is necessary to properly inform patients about what the future holds for them, and the likely benefits of treatment. Despite the various pitfalls in the derivation and validation of prognostic models (or scores), there are an increasing number of useful models available to help patients and clinicians in routine neurology practice. This article considers how such models are best derived, and how their reliability should be assessed, drawing on examples from various different neurological disorders.
Statistics from Altmetric.com
Read the full text or download the PDF:
Other content recommended for you
- CHADS2 and CHA2DS2-VASc score to assess risk of stroke and death in patients paced for sick sinus syndrome
- Prediction of stroke or TIA in patients without atrial fibrillation using CHADS2 and CHA2DS2-VASc scores
- Pay-for-performance programmes reduce stroke risks in patients with type 2 diabetes: a national cohort study
- Derivation and validation of QStroke score for predicting risk of ischaemic stroke in primary care and comparison with other risk scores: a prospective open cohort study
- Impact of heart failure with normal ejection fraction on the occurrence of ischaemic stroke in patients with atrial fibrillation
- Prognosis in patients with transient ischaemic attack (TIA) and minor stroke attending TIA services in the North West of England: The NORTHSTAR Study
- Recurrent transient ischaemic attack and early risk of stroke: data from the PROMAPA study
- LDL-C levels, lipid-lowering treatment and recurrent stroke in minor ischaemic stroke or TIA
- Prognostic value of von Willebrand factor for patients with atrial fibrillation: a meta-analysis of prospective cohort studies
- Risk factors associated with 90-day recurrent stroke in patients on dual antiplatelet therapy for minor stroke or high-risk TIA: a subgroup analysis of the CHANCE trial